Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod IV in Adult Primary ITP
NCT04274452Phase 3Withdrawn
- Sponsor
- argenx
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Antibody Fragments
01
Overview
A Phase 3 trial of efgartigimod alfa in primary immune thrombocytopenia (ITP), sponsored by argenx. Planned start Jun 2020; status: withdrawn.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04274452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274452.